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Summary.-A double-blind trial of the tanned-erythrocyte electrophoretic mobility
test for cancer has been carried out. This included 70 normal subjects as controls,
61 subjects with disease other than cancer, and 229 cancer patients. Slowing values
generally increased in the order given, with certain diseases having values within the
range positive for cancer. Exposure to viral infection also tended to produce false
positives. Slowing values above50o%, however, appear to be definitely associated with
cancer. For the middle range of slowing values (25-50%) there is some overlap be-
tween the 3 groups, so that a statistical probability of the presence of malignancy
is available from the test. With slowing values below250/% there is little likelihood of
cancer. Tumour type influences the test result, as does, to a lesser extent, tumour bulk.
VARIOUS ASSAYS have been reported as
detecting the release oflymphokines when
lymphocytes sensitized to tumour antigens
are exposed to an appropriate tumour-
antigen preparation, or to myelin basic
protein (e.g. Moore & Lajtha, 1977; Pick,
1977). The assay which has generated the
greatest degree of controversy is, perhaps,
the Macrophage Electrophoretic Mobility
(MEM) test of Field & Caspary (1970).
This is dependent upon a decrease in the
electrophoretic mobility of macrophages
when these have been incubated with
lymphocyte supernatants containing the
lymphokine Macrophage Slowing Factor
(MSF). The test is technically very de-
manding, and is very sensitive to the
quality of the guinea-pig peritoneal
exudates (Dickinson & Dyson, 1978)
which are the source of the macrophages
required for the test. Possibly because of
this, the question of the validity of the
test as an assay for sensitized lympho-
cytes, and especially as a method for
detecting malignant disease, has never
been entirely resolved. Some have re-
ported confirmation of the results of Field
& Caspary (1970) (e.g. Pritchard et al.,
1972, 1973; Preece & Light, 1974; Rawlins
et al., 1976). Others, however, have been
unable to confirm their results (e.g.
Crozier et al., 1976; Arvilommi et al., 1977;
Forrester et al., 1977). In a recent study
using laser Doppler electrophoresis, Petty
et al. (1980) found that guinea-pig lympho-
kines reduced the electrophoretic mobility
of guinea-pig macrophages by some 15%,
but were unable to detect any effect of
human lymphokines.
In an attempt to eliminate the problems
associated with guinea-pig macrophages,
Porzsolt et al. (1975) reported that sheep
erythrocytes, treated with tannic acid and
stabilized with sulphosalicylic acid, could
be used as indicator cells in the MEM test.
We were able to reproduce their results
and, in an initial trial, found the test
system to detect the presence of malig-
nancy with a success rate of some 80%
(Dyson & Corbett, 1978). However, we
differed from Porzsolt et al. (1975) who
reported their test system as a modifica-
tion of the MEM test, which is generally
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basis (Dickinson, 1979), in considering the
test using tanned erythrocytes to be non-
immunological, and depending on the
alteration of a physiological factor in the
presence of malignancy (Dyson & Corbett,
1978). Further work has supported the
view that, rather than a lymphokine being
involved, the inhibition of the electro-
phoretic mobility of the tanned erythro-
cytes is due to neutralization of their
negative change on binding myelin basic
protein (the antigen used in the test), the
inhibition being further increased by
histones present as an impurity (Dyson &
Watkinson, submitted for publication).
The affinity of the myelin basic protein
and histones for the erythrocytes is gradu-
ally lost on incubation with lymphocytes,
due to degradation of these proteins by a
proteolytic enzyme on the lymphocyte
surface (Dyson, submitted for publica-
tion). The activity of this enzyme is re-
duced in subjects with malignant disease,
thus the degradation of the myelin basic
protein and histones is reduced, and they
partially retain their affinity for the
tanned erythrocytes, and, therefore, their
effect on electrophoretic mobility (Dyson,
1979). This partial retention of electro-
phoretic mobility inhibition when the pre-
incubation is with lymphocytes derived
from cancer patients gives the impression
of the effect of MSF. However, Ax (1979)
has recently reported that an antigen may
be isolated from human brain extract that,
while not directly affecting erythrocyte
electrophoretic mobility, yet causes re-
lease of a lymphokine capable of reducing
their mobility.
Since our first report (Dyson & Corbett,
1978) a double-blind trial has been in
progress to determine the ability of the
method to distinguish between normal
subjects, those with disease other /than
cancer, and patients with malignant
disease. A sufficient number of subjects
have now been incorporated in the trial
for preliminary conclusions to be reached
regarding the discriminatory ability of the
test, and for experience to be gained in the
factors which influence the reliability of
the test, both those inherent in the test
subject and those due to the test system.
The results for the 360 subjects included
in the test, together with a preliminary
analysis of some of the factors which in-
fluence the test, are therefore presented in
this report.
MATERIALS AND METHODS
Selection of subjects.-At this stage in the
investigation our object was only to determine
the ability ofthe test to discriminate subjects
with known malignant disease from normal
control subjects, and from those with disease
other than cancer, and also to attempt to
assess to what extent tumour site, tumour
bulk and degree of tissue invasion influenced
the test results. The only criterion applied at
this time to the selection of cancer patients
for inclusion in the trial was, therefore, that
a malignant tumour had been diagnosed, and
that radiotherapy or chemotherapy had not
begun. No effect of the age of the subject on
the test result has been detectable in any of
the 3 groups, so age-matching controls to
cancer patients has not been attempted at
this stage.
The method of coding throughout the in-
vestigation was as follows. A number was
allocated to each donor in the clinic where the
blood sample was taken. The records match-
ing each number with name and diagnosis
were not released until the end of the trial.
During preparation oftheincubationmixtures
new numbers were allocated in the laboratory
for that day's blood samples. Thus, the
operator was unaware which incubation mix-
ture corresponded to which blood sample
when electrophoretic measurements were
carried out.
Preparation of lymphocytes.-Defibrinated
blood was used throughout the investigation.
The collection of blood samples and isolation
of lymphocytes (Dyson & Corbett, 1978) was
unchanged, with the exception that Lympho-
cyte Separation Medium (Flow Laboratories,
Irvine, Ayrshire) replaced Ficoll-Paque for
the latter part of the investigation. No
difference in lymphocyte recovery, or in
results, were observed when the 2 media
were compared. Hanks' balanced salt solu-
tion (HBSS) replaced Eagle's Basal Medium
(BEM) for final suspension of the lympho-
cytes..J. E. D. DYSON ET AL.
Brainl extracts. Extracts of hurman brain
(BE) were prepared essentially as previously
described (Dyson & Corbett, 1978). Certain
BE preparations proved more suitable in the
test systemn than others. The reasons for this,
and the minor modifications in mnetliod in-
volved, are described below.
Indicator cells. A fresh aliquot of sheep
erythrocytes, tanned and stabilized with
sulphosalicylic acid (Behring-Werke A.G.,
Marburg-Lahn, West Germany) was prepared
for use each day (Dy.soIn & Corbett, 1978).
Preparationl of solationts. All solutions
were prepared as before (Dyson & Corbett,
1978) except that HBSS was used in place of
BEM. The conductivitv of the HBSS solu-
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Flo. 1. -Results of (louble-blind trial oI1 '360 subjects (lixidel(l into 6 categories. The age ranges were
as follows: (A) 22-54. (13) 24-X4. (C) :33-63. (DJ) 43-69. (FJ) 23-83. (F) 37-61.
tions used for electrophoresis were routinely
checked (Model MCI Mk V. Electronic Tnstru-
inents Ltd, Chertsey) and determined to be
1 515 + 0 021 x 10-2 mho/cm at 25°C.
Electrophoretic mi,ethods. The incubations
of lymphocytes writh BE, and subsequently
of the supernatants with tanned sheep
erythrocytes, have been reported (Dyson &
Corbett, 1978). The onily alteration was the
amount ofBE added, which varied, according
to the preparation employed, from 133 to
330 ug/ml incubation mixture.
Electrophoretic mobilities weredetermined,
and percentage slowings calculated, as pre-
viously described (Dyson & Corbett, 1978)
except that HBSS replaced BEM for electro-
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phoresis. To allow intercomnparison of the
values for residual slowing obtained with
var'ious BE preparations differing in their
slowing of erythrocyte rnobility for a given
BE concentration, the residual slowing
values of Figs 1 2 and 3 halve beeni presented
as:
00 slowNing with BE +lymphocytes
%0 slowA-ing writh BE alone (control)
=slowing as %0 of control
the initial concentration of BE in both tubes
b)eing the same.
For clarity of presentation in Figs 1 and 2.
valuies for residual slowing have l)e(e-n shown
together within each 50% iincrease. The terin
residual slowing" denotes the inhibition of
the electrophoretic mobility of tanne(d
erythrocytes still exerted by an aliquot of BE
after incubation with a given numbei of
l,ymphocNtes.
RESULTS
The double-blind trial
The residual slowing values for the 360
subjects included in the trial are shown in
Fig. 1, separated into 6 categories.
Category A includes all normal controls.
These were fit, healthy subjects with no
known disease, principally hospital staff,
and relatives of patients attending clinics
at Cookridge Hospital. Category B sub-
jects were those with diseases other than
cancer, selected from several different
clinics. The diagnoses for those subjects in
whom the residual slowing value exceeded
3000, are shown in Table I. Subjects with
superficial tumours, basal-cell and
squiamous-cell carcinomas (BCC' and SC'C)
TABLE I. Subjects with disease other than
canceru with slowing > 30°/ of control
D)iagnosis No. > 3:000
l)iabetes 5
Sarcoilosis I
HypertlhvrIoi(lism 2
Gouit
Hypeirlipidlaemia 2
-Haematuria* 1
Rheumatooid ar-thritis 2
Vitiligo I
Hypertensioll I
Infectious mononucleosis 2
Postural liypotenisioin (age 73) 1
Chronic bronclitis I
Infection -with unknown vil'Us 4
* Cancer subsequently dliagnosed.
are shown together in (Category (1 Other
subjects with malignant disease shown
separately are those with bronchial cancer
(D), and with breast cancer (F). All re-
maining cancer subjects are shown to-
gether as a single category (E); no other
individual group of cancer patients being
large enough to justify- separation.
Table 11 presents a statistical analysis
of the data of Fig. l, including values for
the t test for independent means and the
corresponding P. The percent probability
of exceeding a given slowing value is
shown plotted in Fig. 2 for Categories A
to F (omitting Category C), these values
being derived from normalized curves cal-
culated from the data for the separate
categories shown in Fig. 1. In Categories
E and F (Fig. 1) there is a tendency for a
bimodal distribution of slowing values.
However, as the numbers of subjects are
at present insufficient to confirm this, the
normalized cutrves have been calculated on
the basis of a single peak. The statistical
TABLE II. Statistical analysis of the data ofFig. I
Group
Normal controls
Other diseases
Cancer superficial
Cancer bronchus
Cancer various
Cancer breast
Alean + s.(.
24-3 + 16-)
30-6+ 12-8
34-1 +21-8
35-4 + 14-0
46-4 + 22-6
44-9+ 213:1
t test for independlenit meanis
vS niormal controls 1s otler (liseases
t f) t P
2-365
1*971
4-056
6-885
6-084
<0-05 > 0-02
<0-1 >0-05
<0-001
<<0 001
<0-001
0-825
1985
4-978
4-46(6
<0.5 > 0-4
<01 >005
< 0*001
<0 001J. E. D. DYSON ET AL.
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FiG. 2.- Categories A, B, D, E, F: Percent
probability of exceeding a given slowing
value. Normalized curves calculated from
the datafor the separate categories ofFig. 1,
and the values obtained from tables of
normal probability integrals.
tables of Fisher & Yates (1970) were used
to obtain the values in Table II and Fig. 2.
Factors influencing residual slowing
Fig. 3 shows the residual slowing as a
function of lymphocyte number of a
normal subject tested at 3-weekly inter-
vals over 9 weeks. In the absence ofa viral
infection such values are typical ofnormal
control subjects when a satisfactory BE
preparation is used. On viral infection,
test values increase 2 to 3 days before
clinical symptoms are evident and then
decline, returning to normal within 2-4
weeks. Reproducibility of results for sub-
jects with malignant disease has been
more difficult to assess, as patients start
therapy after the initial test, and the effect
of this on subsequent test results cannot
be separated from experimental variation.
However, several patients are at present
being followed on completion of therapy
and, although slowing values differ from
patient to patient, the reproducibility at
2-3-week intervals is comparable to that
for normal subjects.
On replicate determinations with separ-
ate blood samples taken from the same
donor on the same day, and processed in
parallel, the standard deviation never
exceeded 7%, the same order ofmagnitude
0 60 * t PV--V 2-11-78
c 60 '
o
o 40 \'
0 20
0
IA 0
0 1 2 3 4 5
Lymphocyte number x 106
FIa. 3. Reproducibility of residual slowing
values for a normal control subject over a
9-week period. Tested at 3-weekly intervals
on dates shown in Figure. Slowing values
as function of lymphocyte number. BE
1 mg/3 ml, 18h incubation. Bars show s.d.
as the standard deviation in the deter-
mination of individual slowing values.
During the double-blind trial several
different preparations of BE were used,
some yielding better differentiation be-
tween cancer patients and normal controls
than others. There appear to be 2
principal reasons for this: (i) the addition
of 5 x 106 lymphocytes to 1 mg/3 ml ofthe
BE preparation used in Fig. 3 caused the
slowing to decrease to a plateau at 0 to
10% slowing. With subsequent prepara-
tions, however, a plateau was reached at
about 20%, decreasing the difference
between normal controls and cancer
patients by up to 20%. (ii) The concen-
tration of BE necessary to cause 70-80%
inhibition of electrophoretic mobility
changed from 1 mg/3 ml in the earlier
preparations to 200 to 500 ,tg/3 ml in the
later preparations. These 2 criteria,
lower plateau and decreased inhibition
for a given BE concentration, cause in-
creased differentiation between normal
subjects and those with malignant disease.
Considerable care is necessary, therefore,
to prepare extracts which will provide
optimum results, and experience has
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shown the following points are of im-
portance.
Before defatting, homogenization, with
the minimum amount of water, generally
produces a satisfactory preparation. Addi-
tion of KCI or NaCl to the homogenate,
wvhich increases the extraction of histone,
should be avoided. It is preferable that
the pH of extraction should not drop
below 2 0, to prevent undue extraction
of histone. Brain tissues should be
obtained as soon as possible after death,
and either processed or frozen. This re-
duces the heterogeneity of the final pre-
paration due to protein degradation.
An alternative, if the BE preparation is
unsuitable, is fractionation to remove
excess histone. Passage ofthe BE prepara-
tion through a column of CM-cellulose
(Whatman CM52 microgranular) in 0-2M
Na acetate results in adsorption of the
basic proteins. A suitable preparation of
BE (principally myelin basic protein) may
then be eluted with 0-7-0-9M Na acetate,
though these concentrations may vary if
the proteins are heterogeneous, due to
degradation.
DISCUSSION
A possible explanation for some of the
observed high values (>300%) for residual
slowing in normal subjects (Fig. IA) may
be a sub-clinical viral infection of the
donor. Similar high -values have been
noted in normal subjects with a virus in-
fection during studies of the mechanism
of the assay system, even when symptoms
wvere not apparent until several days later.
The mean of the test results (Fig. lB and
Table II) also shifts to a higher value when
certain diseases are present: 4 subjects
with viral infection and 2 with infectious
mononucleosis all had test results > 30%
(Table I) supporting the view that viral
infection leads to high test values. Tissue
inflammation may have the same effect,
since 2 subjects with gout and 2 with
rheumatoid arthritis are also included
(Table I). Similar positive results for
diseases other than cancer have been seen
32
in the MEM test (e.g. Pritchard, 1979). It
is not yet apparent why the other diseases
in Table I should show high values. It is
interesting, however, that all 5 diabetic
subjects had high values.
For Category E and F cancers (Fig. 1)
slowing exceeding 5000 definitely appears
to be associated with malignancy (Fig. 2).
For slowing values between 25 and 50%0,
however, a statistical probability only can
at present be assigned to the possibility of
malignancy (Fig. 2), the degree of con-
fidence depending on the extent to which
certain diseases other than cancer, which
also give high values, can be eliminated.
For slowing less than 25% there is little
statistical probability of cancer (Fig. 2).
Thus, the assay system may now be of
limited use to assist in the detection of
malignant diseases where slowing values
in the upper range are obtained, possibly
with repeated tests to overcome the
possible effect of exposure to a viral
infection. Greater use of the assay system
must, however, await a more detailed
knowledge of the factors influencing the
test results in the medium range of slow-
ing. Further improvements in technique
may also enable us to increase the re-
liability of detection of malignant disease
within this range.
There is some suggestion that tumour
type influences the response in the test, as
shown by the different distributions of
bronchial cancer (Figs ID and 2) and
breast and other cancers (Figs 1E, IF and
2), and this point will be the subject of
further study. Tumour mass also appears
to affect the test values, a heavy tumour
load generally causing results to be in the
low range. This may contribute to the
generally lower values in the bronchial
cancer group, who tended to have an
above-average tumour mass. Patients with
superficial tumours usually responded in
the low range suggesting that tissue in-
vasion is a prerequisite to response in the
test.
Included in the double-blind trial were
many patients who had undergone radio-
therapy or chemotherapy subsequent to454 J. E. 1). DYSON ET AL.
surgery. The extent to which these sub-
jects were free of microscopic tumour is
not known, and will not be evident for
some time. Thus, the time taken for test
values to revert to normal when the sub-
jects are free of tumour is not yet known.
Careful follow-up of selected groups of
cancer patients will show us whether this
test can be of use for prognosis in these
situations.
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